Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology
Open Access
- 2 April 2012
- journal article
- Published by Springer Science and Business Media LLC in Journal of Neuroinflammation
- Vol. 9 (1), 62
- https://doi.org/10.1186/1742-2094-9-62
Abstract
Background A growing body of evidence indicates that inflammation is one of the earliest neuropathological events in Alzheimer's disease. Accordingly, we have recently shown the occurrence of an early, pro-inflammatory reaction in the hippocampus of young, three-month-old transgenic McGill-Thy1-APP mice in the absence of amyloid plaques but associated with intracellular accumulation of amyloid beta petide oligomers. The role of such a pro-inflammatory process in the progression of the pathology remained to be elucidated. Methods and results To clarify this we administered minocycline, a tetracyclic derivative with anti-inflammatory and neuroprotective properties, to young, pre-plaque McGill-Thy1-APP mice for one month. The treatment ended at the age of three months, when the mice were still devoid of plaques. Minocycline treatment corrected the up-regulation of inducible nitric oxide synthase and cyclooxygenase-2 observed in young transgenic placebo mice. Furthermore, the down-regulation of inflammatory markers correlated with a reduction in amyloid precursor protein levels and amyloid precursor protein-related products. Beta-site amyloid precursor protein cleaving enzyme 1 activity and levels were found to be up-regulated in transgenic placebo mice, while minocycline treatment restored these levels to normality. The anti-inflammatory and beta-secretase 1 effects could be partly explained by the inhibition of the nuclear factor kappa B pathway. Conclusions Our study suggests that the pharmacological modulation of neuroinflammation might represent a promising approach for preventing or delaying the development of Alzheimer's disease neuropathology at its initial, pre-clinical stages. The results open new vistas to the interplay between inflammation and amyloid pathology.Keywords
This publication has 103 references indexed in Scilit:
- Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention TrialInternational Journal of Geriatric Psychiatry, 2012
- Probing the Biology of Alzheimer's Disease in MiceNeuron, 2010
- Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive ImpairmentJournal of Neuropathology and Experimental Neurology, 2009
- Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's diseaseGlia, 2009
- Phosphorylation of the Translation Initiation Factor eIF2α Increases BACE1 Levels and Promotes AmyloidogenesisNeuron, 2008
- Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)Archives of Neurology, 2008
- Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and preventionJournal of Cellular and Molecular Medicine, 2008
- Inflammatory changes parallel the early stages of Alzheimer diseaseNeurobiology of Aging, 2007
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse modelNature Medicine, 2006